Key result
Recent developments in non-alcoholic fatty liver disease focus on new diagnostic biomarkers and treatment approaches, as there are currently no licensed methods for treating the disease.
This review summarizes recent developments in the definition, diagnosis, and treatment of non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver diseases: 25% of the population of European countries have signs of NAFLD, 10–20% of patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In most people, NAFLD is not diagnosed, prognosis is inaccurate, and there are no licensed methods of treating the disease. In this review, we discuss some recent developments in NAFLD, focusing on disease definition, diagnosis, and treatment.
No takes yet. Share an insight, caveat, or question.
Sergienko et al. (2023) conducted a review in Non-alcoholic fatty liver disease (NAFLD). Diagnosis and treatment approaches was evaluated. Recent developments in non-alcoholic fatty liver disease focus on new diagnostic biomarkers and treatment approaches, as there are currently no licensed methods for treating the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: